Rhizen Pharmaceuticals S.A. Announces Presentations on Tenalisib (RP6530) at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
29. Mai 2018 07:00 ET
|
Rhizen Pharmaceuticals SA
La Chaux-de-Fonds, Switzerland, May 29, 2018 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A., a clinical-stage biotechnology company developing Tenalisib (RP6530), a highly selective and orally...
Rhizen Pharmaceuticals S.A. receives FDA Fast Track Designation for Tenalisib (RP6530), a highly selective dual PI3K delta/gamma inhibitor for the treatment of patients with relapsed and/or refractory Cutaneous T-cell Lymphoma (CTCL)
13. April 2018 07:00 ET
|
Rhizen Pharmaceuticals SA
La Chaux-de-Fonds, Switzerland, April 13, 2018 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A., today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation...
Rhizen Pharmaceuticals S.A. receives FDA orphan-drug designation for Tenalisib (RP6530) for treatment of cutaneous T-cell lymphoma (CTCL)
09. April 2018 07:00 ET
|
Rhizen Pharmaceuticals SA
La Chaux-de-Fonds, Switzerland, April 09, 2018 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A., today announced that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation...
Rhizen Pharmaceuticals S.A. announces clinical data presentations for Tenalisib (RP6530) in R/R T-cell lymphoma at the upcoming 10th Annual T-Cell Lymphoma Forum in La Jolla, CA, USA
29. Januar 2018 07:00 ET
|
Rhizen Pharmaceuticals SA
La Chaux-de-Fonds, Switzerland, Jan. 29, 2018 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A., today announced that updated clinical data for Tenalisib (RP6530), the company’s highly selective and...
Rhizen Pharmaceuticals S.A. receives FDA orphan-drug designation for Tenalisib (RP6530) for treatment of peripheral T-cell lymphoma (PTCL)
22. Dezember 2017 08:00 ET
|
Rhizen Pharmaceuticals SA
La Chaux-de-Fonds, Switzerland, Dec. 22, 2017 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A., today announced that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation...
Rhizen Pharmaceuticals S.A. receives FDA Fast Track Designation for RP6530 (tenalisib), a highly selective dual PI3K delta/gamma inhibitor for the treatment of patients with relapsed/refractory peripheral T-cell lymphoma (PTCL)
09. Dezember 2017 08:00 ET
|
Rhizen Pharmaceuticals SA
La Chaux-de-Fonds, Switzerland, Dec. 09, 2017 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A., today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for...
Rhizen Pharmaceuticals S.A. announces clinical and preclinical data presentations at the upcoming 59th American Society of Hematology (ASH) Annual Meeting & Exposition in Atlanta, GA, USA
05. Dezember 2017 07:00 ET
|
Rhizen Pharmaceuticals SA
La Chaux-de-Fonds, Switzerland, Dec. 05, 2017 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A., today announced that updated data for RP6530 (tenalisib), the Company’s highly selective and orally...
Rhizen Pharmaceuticals S.A. to present Phase 1 clinical and additional preclinical data of RP6530 (dual PI3K delta/gamma inhibitor) in hematological malignancies
03. Dezember 2014 07:00 ET
|
Rhizen Pharmaceuticals SA
La Chaux-de-Fonds, Switzerland, Dec. 3, 2014 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A. announces Phase 1 clinical and
additional preclinical data presentations for RP6530, a novel dual
PI3K...
Rhizen Pharmaceuticals S.A. to present preclinical data of RP6530 (dual PI3K delta/gamma inhibitor) in Multiple Myeloma
18. November 2014 07:00 ET
|
Rhizen Pharmaceuticals SA
La Chaux-de-Fonds, Switzerland, Nov. 18, 2014 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A. announces a poster presentation for
RP6530, a novel dual PI3K delta/gamma inhibitor in Multiple
Myeloma.
...
Rhizen Pharmaceuticals S.A. announces initiation of a "First in Human" Phase-1 trial of RP6530, a dual PI3K delta/gamma inhibitor, in patients with hematological malignancies
06. Dezember 2013 06:10 ET
|
Rhizen Pharmaceuticals SA
La Chaux-de-Fonds, Switzerland, Dec. 6, 2013 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A. today announced the initiation
of a "first in human" Phase-1 study of RP6530, a...